EligibleTrials

ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis

Recruiting · NCT06775860 · Interventional (participants receive a specific treatment) · Lead sponsor: Beijing InnoCare Pharma Tech Co., Ltd.

View the official record on ClinicalTrials.gov →
Eczema

Interventions studied

ICP-332 Placebo TabletsICP-332 Tablets

What this trial is about

A randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of oral ICP-332 in subjects with moderate to severe atopic dermatitis

Who can take part

Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

60 locations listed.

Showing 60 of 62 listed sites. See the official record for the complete list.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.